A Review of Osteocyte Function and the Emerging Importance of Sclerostin

被引:140
作者
Compton, Jocelyn T. [1 ]
Lee, Francis Y. [1 ]
机构
[1] Columbia Univ, Med Ctr, Ctr Orthopaed Res, New York, NY 10032 USA
关键词
INHIBITING BONE-RESORPTION; SOST GENE MUTATION; VAN-BUCHEM-DISEASE; SERUM SCLEROSTIN; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; PROSTATE-CANCER; FRACTURE REPAIR; TISSUE STRAIN; ANTIBODY;
D O I
10.2106/JBJS.M.01096
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Osteocytes, derived from osteoblasts, reside within bone and communicate extensively with other bone cell populations to regulate bone metabolism. The mature osteocyte expresses the protein sclerostin, a negative regulator of bone mass. In normal physiologic states, the protein sclerostin acts on osteoblasts at the surface of bone and is differentially expressed in response to mechanical loading, inflammatory molecules such as prostaglandin E2, and hormones such as parathyroid hormone and estrogen. Pathologically, sclerostin dysregulation has been observed in osteoporosis-related fractures, failure of implant osseous integration, metastatic bone disease, and select genetic diseases of bone mass. An antibody that targets sclerostin, decreasing endogenous levels of sclerostin while increasing bone mineral density, is currently in phase-III clinical trials. The osteocyte has emerged as a versatile, indispensable bone cell. Its location within bone, extensive dendritic network, and close communication with systemic circulation and other bone cells produce many opportunities to treat a variety of orthopaedic conditions.
引用
收藏
页码:1659 / 1668
页数:10
相关论文
共 126 条
  • [31] THE EFFECT OF LEUKEMIA INHIBITORY FACTOR ON BONE INVIVO
    CORNISH, J
    CALLON, K
    KING, A
    EDGAR, S
    REID, IR
    [J]. ENDOCRINOLOGY, 1993, 132 (03) : 1359 - 1366
  • [32] Cui L, 2013, J MUSCULOSKEL NEURON, V13, P178
  • [33] Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism
    Dai, JL
    Keller, J
    Zhang, J
    Lu, Y
    Yao, Z
    Keller, ET
    [J]. CANCER RESEARCH, 2005, 65 (18) : 8274 - 8285
  • [34] The Osteocyte: An Endocrine Cell . . . and More
    Dallas, Sarah L.
    Prideaux, Matthew
    Bonewald, Lynda F.
    [J]. ENDOCRINE REVIEWS, 2013, 34 (05) : 658 - 690
  • [35] Dynamics of the transition from osteoblast to osteocyte
    Dallas, Sarah L.
    Bonewald, Lynda F.
    [J]. SKELETAL BIOLOGY AND MEDICINE, 2010, 1192 : 437 - 443
  • [36] Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
    Drake, Matthew T.
    Srinivasan, Bhuma
    Moedder, Ulrike I.
    Peterson, James M.
    McCready, Louise K.
    Riggs, B. Lawrence
    Dwyer, Denise
    Stolina, Marina
    Kostenuik, Paul
    Khosla, Sundeep
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (11) : 5056 - 5062
  • [37] Eddleston A, 2009, J BONE MINER RES, V24, P1662, DOI [10.1359/JBMR.090403, 10.1359/jbmr.090403]
  • [38] Regulation of bone remodeling by the central and peripheral nervous system
    Elefteriou, Florent
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2008, 473 (02) : 231 - 236
  • [39] Buried alive: How osteoblasts become osteocytes
    Franz-Odendaal, TA
    Hall, BK
    Witten, PE
    [J]. DEVELOPMENTAL DYNAMICS, 2006, 235 (01) : 176 - 190
  • [40] Prostaglandin E2 Signals Through PTGER2 to Regulate Sclerostin Expression
    Genetos, Damian C.
    Yellowley, Clare E.
    Loots, Gabriela G.
    [J]. PLOS ONE, 2011, 6 (03):